Results 161 to 170 of about 19,293 (297)

Dynamic evolution of NK cells and immune remodeling mediated by CRS + HIPEC: prognostic mechanisms and therapeutic implications for malignant peritoneal mesothelioma [PDF]

Yitong Liu, Qidi Zhao, Xin‐Li Liang, Ru Ma, Yan‐Dong Su, Rui Yang, Tian Wei, He‐Liang Wu, Yu‐Bin Fu, Yong Cui, Yang Yu, Bing Li, Yan Li   +12 more
openalex   +1 more source

Physical, psychological and nutritional outcomes in a cohort of Irish patients with metastatic peritoneal malignancy scheduled for cytoreductive surgery (CRS) and heated intrapertioneal chemotherapy (HIPEC): An exploratory pilot study

, 2020
Lisa Loughney, Noel McCaffrey, Claire Timon, Joshua Grundy, Andrew McCarren, Ronan A. Cahill, Niall M. Moyna, Jürgen Mulsow   +7 more
openalex   +2 more sources

Implementation of an enhanced recovery after surgery (ERAS) program in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: study protocol for a prospective multicenter interventional trial (EPICH study)

Pleura and Peritoneum
This study aims to evaluate the clinical impact of introducing an Enhanced Recovery After Surgery (ERAS) protocol in the management of patients undergoing cytoreductive surgery (CRS), with or without hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella Manuela, Pagano Eva, Giacometti Lisa, Cinquegrana Armando, Pellegrino Luca, Evangelista Andrea, Saliva Alessandra, Cerutti Alessandro, Borghi Felice   +8 more
doaj   +1 more source

Don’t Call It a Comeback—HIPEC for Gastric Cancer

Annals of Surgical Oncology, 2022
B. Badgwell
semanticscholar   +1 more source

231 – Should We Be Doing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Signet Ring Cell Appendiceal Adenocarcinoma? a Study from the US Hipec Collaborative

, 2019
Nick C. Levinsky, Mackenzie C. Morris, Koffi Wima, Jonathan Sussman, Syed Shamshad Ahmad, Jordan M. Cloyd, Charles W. Kimbrough, Keith F. Fournier, Andrew Lee, Seán Dineen, Sophie Dessureault, Jula Veerapong, Joel Baumgartner, Callisia N. Clarke, Charles A. Staley, Shishir K. Maithel, Jennifer L. Leiting, Travis E. Grotz, Laura Lambert, Ryan J. Hendrix, Sean M. Ronnekleiv‐Kelly, Courtney Pokrzywa, Mustafa Raoof, Oliver S. Eng, Fabian M. Johnston, Jonathan B. Greer, Sameer H. Patel   +26 more
openalex   +1 more source

HIPEC στον καρκίνο του στομάχου

, 2021
Gastric cancer constitutes the third most common malignancy worldwide and the third most common cause of death due to malignancy. The incidence of the disease differs depending on the area, the race and the gender. The prognosis as well as the treatment options depend largely on the stage of the disease.
openaire   +1 more source

Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis [PDF]

, 2016

core   +1 more source

#518 Validation of surgical peritoneal cancer index (SPCI) as a prognostic marker in ovarian cancer patients undergoing interval cytoreductive surgery & hyperthermic intraperitoneal chemotherapy (ICS-HIPEC) [PDF]

, 2023
Babul Bansal, M. D. Ray, S. V. S. Deo, Ashutosh Mishra, Areendam Barua, N. Premanand   +5 more
openalex   +1 more source

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy [PDF]

, 2016
Cedric Demtröder, Clemens Tempfer, Jürgen Zieren, Marc A. Reymond, Nurettin Albayrak, Ramy Girshally   +5 more
core   +1 more source

Treatment planning software for HIPEC

, 2023
Peritoneal metastases (PM) predominantly originate from primary cancers such as colorectal, ovarian and gastric cancer. Survival rates decrease dramatically when metastases develop in the peritoneal cavity. The combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) offers a treatment option that can ...
openaire   +2 more sources